Patent ID: 6602888
Filing Date: 2003-08-05
Classification: A61K,A61P,C07C,C07D

Abstract:
A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an amount of a compound effective to treat benign prostatic hyperplasia, which compound:a. binds to a human &agr;1C adrenergic receptor with a binding affinity greater than ten-fold higher than the binding affinity with which the compound binds to a human &agr;1A adrenergic receptor, a human &agr;1B adrenergic receptor, and a human histamine H1 receptor; b. binds to a human &agr;2 adrenergic receptor with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to such &agr;1C adrenergic receptor; and c. binds to a calcium channel with a binding affinity which is greater than ten-fold lower than the binding affinity with which the compound binds to a human &agr;1C adrenergic receptor.